News|Articles|June 10, 2026

FDA Approves Tocilizumab-bavi for CAR-T-Induced CRS, Pediatric COVID-19

Listen

0:00 / 0:00

Key Takeaways

Indication expansion now includes CAR‑T–associated severe or life-threatening CRS for adults and pediatric patients aged ≥2 years, supporting guideline-concordant IL‑6 receptor blockade in onco-hematology.
Pediatric COVID‑19 labeling now covers hospitalized patients ≥2 years on systemic corticosteroids who require oxygen, noninvasive/invasive ventilation, or ECMO, paralleling evidence for hyperinflammatory severe disease.
Formulary substitution in CRS protocols could reduce total episode-of-care costs versus branded Actemra, especially with broader CAR‑T adoption in community oncology and academic centers.
Prior FDA clearance (September 2023) spanned major rheumatology uses, and the new acute-care indications extend utilization into high-intensity inpatient pathways.
Reference tocilizumab’s ~$2.7–$3.1B 2024 global sales highlight the economic stakes of biosimilar competition and the strategic value of a comprehensive IL‑6 inhibitor label.

The FDA approved a supplemental BLA for Organon's tocilizumab biosimilar Tofidence.

The FDA has approved a supplemental Biologics License Application (sBLA) for tocilizumab-bavi (Tofidence; Organon), its intravenous tocilizumab biosimilar, expanding the product's approved indications to include CRS and broadening its existing COVID-19 indication, announced Organon on June 10 .¹ The approval adds treatment of CAR-T cell-induced severe or life-threatening cytokine release syndrome (CRS) and expands the COVID-19 indication to include hospitalized pediatric patients aged 2 years and older who require respiratory support.

Tocilizumab-bavi is a biosimilar to tocilizumab (Actemra), the reference biologic manufactured by Genentech and marketed by Roche. The newly approved indications bring the tocilizumab-bavi label into alignment with that of the reference product in these settings, broadening access to a lower-cost alternative for institutions managing 2 of the most resource-intensive inflammatory conditions encountered in hospital and oncology care.

New Indications: CRS and COVID-19

The CRS indication covers adults and pediatric patients 2 years of age and older with CAR-T cell-induced severe or life-threatening CRS. CAR-T therapies, which redirect a patient’s own immune cells to target cancer, have transformed outcomes in hematologic malignancies but carry a significant risk of CRS, a potentially life-threatening systemic inflammatory response. Tocilizumab-bavi, an interleukin-6 (IL-6) receptor antagonist, is a cornerstone of CRS management and is included in major oncology guidelines for this indication.

The COVID-19 indication covers hospitalized adults and pediatric patients 2 years of age and older who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation. This mirrors the evidence base established for reference tocilizumab in severe COVID-19, where IL-6 pathway blockade has been shown to reduce mortality in patients with hyperinflammatory disease.

“The approval of these new indications for Tofidence is a vital step forward in expanding access to treatment options that address critical needs, including for patients facing CRS, a serious side effect of CAR-T therapies,” said Jon Martin, US Commercial Lead, Biosimilars and Established Brands at Organon, in a statement. “In the US, biosimilar adoption may help reduce the affordability burden of high-cost brand biologics on the health care system. By expanding the use of Tofidence, we continue to advance our biosimilars portfolio and our commitment to broadening access to high-quality treatment options for patients in need.”

Managed Care and Biosimilar Access Implications

For payers and pharmacy directors, the expanded label is significant. CAR-T therapy utilization has grown rapidly across both academic medical centers and community oncology settings, and CRS management protocols account for a meaningful share of post-infusion costs. Formulary inclusion of a biosimilar tocilizumab for CRS management could generate meaningful savings relative to branded Actemra, particularly as CAR-T indications continue to expand across B-cell malignancies and, increasingly, autoimmune diseases.

The COVID-19 indication, while less frequently triggered in the current epidemiological environment, retains clinical relevance for high-risk hospitalized patients with severe hypoxemia and may become more salient during future respiratory virus surges.

Tocilizumab-bavi was originally approved by the FDA in September 2023 for Actemra’s rheumatology indications, including rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis. The sBLA approval announced today significantly broadens the product's use in acute-care settings. Reference tocilizumab generated approximately $2.6 billion in global sales in 2024, underscoring the commercial and access significance of biosimilar competition in this space.²

The approval makes tocilizumab-bavi one of the more comprehensively labeled tocilizumab biosimilars available in the US market, covering the full breadth of IL-6 receptor antagonist use from chronic inflammatory disease management to acute oncologic and infectious emergencies.¹

References